Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The flower of the opium poppy, Papaver somniferum, showing the sexual parts. Allen et al. have used RNA interference to modify the alkaloid content of this poppy (see p. 1559). Credit: Jeremy Burgess/Photo Researchers, Inc.
Biotech companies could have their say in setting up standards for regulatory approval of cutting edge drugs, as they benefit from parallel scientific advice from Europe and the US.
Bioethicist Daniel Callahan argues that, with infinite demand and finite resources, pricey biotech drugs and the present US healthcare system are unsustainable.
China is a growing biotech player whose main competitive edge lies in low development costs. But will inexperienced money men and a disinterested pharmaceutical industry hold it back? Sabine Louët investigates.
Despite entering its maturation phase, the recombinant protein sector will continue to drive the growth of medical biotechnology over the next six years.
The Health Biotechnology Innovation in Developing Countries supplement presents the results of an in-depth study of the health biotechnology sector of seven developing nations.
